Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ORION PHARMA from Mechelen, company number BE0821527741, closed financial year 2025 with a result of € 137,817 after tax. For that financial year ORION PHARMA recorded revenue of € 4.4 million and equity of € 822,015. Compared with financial year 2024, the result moved from € 133,253 to € 137,817. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 20, 2026.
€ 822,015
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 137,817
▲ 3% vs 2024
Profit after tax over the fiscal year.
€ 427,711
▲ 119% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 803,465.
People and assets in 2025
21.6
▲ 13.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.6 million
▲ 82% vs 2024
€ 122,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 25,489
▼ 12% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5,802
▼ 97% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 1 days on average.
€ 388,516
▲ 18% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 4,460,104 | € 3,449,951 | € 3,513,295 | € 4,437,772 | ▲ 26% |
| Profit after taxes | € 60,344 | € 84,050 | € 133,253 | € 137,817 | ▲ 3% |
| Equity | € 466,895 | € 550,945 | € 684,198 | € 822,015 | ▲ 20% |
| Total debts | € 295,518 | € 533,301 | € 525,869 | € 394,318 | ▼ 25% |
| Cash | € 471,116 | € 32,132 | € 195,116 | € 427,711 | ▲ 119% |
| Retained profit | € 448,345 | € 532,395 | € 665,648 | € 803,465 | ▲ 21% |
| Balance sheet total | € 762,413 | € 1,084,246 | € 1,210,067 | € 1,216,334 | ▲ 1% |
| Employees (FTE) | 6.6 | 6.4 | 7.7 | 21.6 | ▲ 13.9 |
Key figures of ORION PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ORION PHARMA?
What happened at ORION PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 137,817 (▲ 3% vs 2024). filed late Source: NBB ↗
- New establishment in Mechelen. KBO
- Start of the company according to the CBE. KBO
In short
From € 60,344 profit in 2022 to € 137,817 profit in 2025.
Paid € 228,944 in corporate taxes since 2022.
Best year ever: 2025, with € 137,817 profit.
Pays suppliers within 1 days on average.
A new publication or filing at ORION PHARMA? We notify you, reason included.
Follow ORION PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ORION PHARMA are Robert Borgdorf and Hao Pan.
Directors
According to the 2025 annual accounts
Robert Borgdorf
Director
Hao Pan
Director
Establishments
Establishment units
Physical locations of this company
Battelsesteenweg 455 box D
2800 Mechelen
Battelsesteenweg 455D
2800 Mechelen
Active since 17 December 2009
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →HEALTH MANAGEMENT ASSOCIATES
€ -6,502 gross margin · 2025
Saint - Frères (Belgique)
KOOP PUTBORINGEN
€ 213,051 gross margin · 2025
I.M. Belgium
€ 288,775 gross margin · 2024
VMware Belgium
€ 11.4 million revenue · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0821.527.741
- VAT number
- BE 0821.527.741
- Registered office
- Battelsesteenweg 455 bus D, 2800 Mechelen
- Names & denominations
- ORION PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 December 2009
- Peppol
- Active · Active since 6 Jan 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Markt- en opinieonderzoek
Activiteiten van reclamebureaus